Compare KE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | CTMX |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.2M | 596.2M |
| IPO Year | 2014 | 2015 |
| Metric | KE | CTMX |
|---|---|---|
| Price | $25.35 | $4.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $28.00 | $12.10 |
| AVG Volume (30 Days) | 120.4K | ★ 9.2M |
| Earning Date | 05-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,486,727,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | $27.22 |
| P/E Ratio | $46.09 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.41 | $0.40 |
| 52 Week High | $33.19 | $8.21 |
| Indicator | KE | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 43.27 |
| Support Level | $23.38 | $3.55 |
| Resistance Level | $31.17 | $4.64 |
| Average True Range (ATR) | 1.03 | 0.59 |
| MACD | 0.40 | -0.09 |
| Stochastic Oscillator | 88.67 | 3.75 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.